Death is associated with complement C3 depletion in cerebrospinal fluid of patients with pneumococcal meningitis. by Goonetilleke, U. R. et al.
doi:10.1128/mBio.00272-11.
 3(2): .mBio. Meningitis
in Cerebrospinal Fluid of Patients with Pneumococcal 
Death Is Associated with Complement C3 Depletion2012. 
U. R. Goonetilleke, M. Scarborough, S. A. Ward, et al.
 
 
Patients with Pneumococcal Meningitis
C3 Depletion in Cerebrospinal Fluid of 
Death Is Associated with Complement
 http://mbio.asm.org/content/3/2/e00272-11.full.html
Updated information and services can be found at: 
MATERIAL
SUPPLEMENTAL
 http://mbio.asm.org/content/3/2/e00272-11.full.html#SUPPLEMENTAL
REFERENCES
 http://mbio.asm.org/content/3/2/e00272-11.full.html#ref-list-1
This article cites 47 articles, 18 of which can be accessed free at:
CONTENT ALERTS
 more>>article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this
 
 http://journals.asm.org/subscriptions/To subscribe to another ASM Journal go to: 
 http://mbio.asm.org/misc/contentdelivery.xhtml
Information about Print on Demand and other content delivery options: 
 http://mbio.asm.org/misc/reprints.xhtmlInformation about commercial reprint orders: 
 
m
bio.asm
.org
 o
n
 August 10, 2012 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
Death Is Associated with Complement C3 Depletion in Cerebrospinal
Fluid of Patients with Pneumococcal Meningitis
U. R. Goonetilleke,a* M. Scarborough,b S. A. Ward,a S. Hussain,c A. Kadioglu,d and S. B. Gordona
Liverpool School of Tropical Medicine, Liverpool, United Kingdoma; John Radcliffe Hospital, Oxford, United Kingdomb; Department of Infection Immunity and
Inflammation, University of Leicester, Leicester, United Kingdomc; and Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdomd
* Present address: Genzyme (A Sanofi Company), Haverhill, Suffolk, United Kingdom.
ABSTRACT Pneumococcal meningitis can lead to death or serious neurological sequelae as a result of the host inflammatory re-
sponse. We investigated the association between host response protein expression and outcome in patients with pneumococcal
meningitis. Cerebrospinal fluid (CSF) was obtained from 80 patients with pneumococcal meningitis (40 nonsurvivors and 40
survivors) and 10 normal controls. Candidate proteins were analyzed for an association with survival. Complement C3 levels
were 5-fold lower in nonsurvivors than in survivors (P< 0.05). This C3 reduction was not associated with lower levels in serum,
indicating a compartmentalized CSF response. Transferrin levels were significantly higher in CSF (but not serum) from nonsur-
vivors than in CSF from survivors, suggestive of blood-brain barrier damage. Classical apoptosis proteins caspase 3 and
apoptosis-inducing factor were not present in CSF. Expression of creatine kinase BB in clinically infected CSF suggested neuro-
nal necrosis, but there was no clear association between level of expression and clinical outcome. Increased blood-brain barrier
permeability and complement C3 depletion may have a role in determining outcome from bacterial meningitis. Therapeutic use
of citicoline or caspase inhibitors is unlikely to have beneficial effects in patients with meningitis.
IMPORTANCE We previously identified proteins associated with clinical outcome in patients diagnosed with pneumococcal men-
ingitis in a pilot proteomics study of cerebrospinal fluid (CSF). In this article, we have quantitatively assayed specific proteins
identified from this previous proteomics analysis along with proteins associated with cell death by usingWestern blotting.
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Despite many major advances in our understanding of thepathogenesis of pneumococcal meningitis, there has been lit-
tle therapeutic progress in the last 60 years. This is predominantly
due to the fact that bacterial cell wall products released in the
cerebrospinal fluid (CSF) initiate a cascade of destructive host
immune responses that are not ameliorated by currently available
treatments.
We have shown that complement C3 depletion and increased
blood-brain barrier permeability may have a role in determining
the outcome of bacterial meningitis. In addition, therapeutic use
of citicoline or caspase inhibitors is unlikely to have a beneficial
effect in patients with meningitis, as these pathways were not de-
monstrably disrupted.
Streptococcus pneumoniae is the most common pathogen asso-
ciatedwith bacterialmeningitis beyond the neonatal period (1). In
Malawi, pneumococcal meningitis has a high fatality rate of 67%
(2). Survivors often develop long-term neurological sequelae, in-
cluding hearing loss and focal neurological deficits (3, 4). Our
previous pilot proteomic study of CSF in patients with pneumo-
coccal meningitis revealed that clinically infected CSF contains
several thousand proteins of central nervous system (CNS) and
serum origin. A proteomic comparison of nonsurvivors and sur-
vivors allowed detection of proteins associatedwith survival (5). It
was therefore necessary to determine if this correlation, and sub-
sequent hypotheses generated, could be confirmed in a larger
sample size.
CSF proteins originate from serum and from local intracranial
production. A breakdown in the integrity of the blood-brain bar-
rier allows increased levels of serum proteins to access the CSF
(6–8). This contributes to the development of increased intracra-
nial pressure, hydrocephalus, brain edema, and cerebral ischemia
(9, 10), all of which can cause neuronal cell death (11, 12). In
animal models, cell death was found to occur via three distinct
pathways: classic caspase 3-dependent cell death (i.e., apoptosis),
caspase 3-independent cell death (i.e., pyknosis), and necrosis (13,
14). Caspase inhibitors and citicoline, an intermediate in the syn-
thesis of phosphorylcholine in mitochondrial and cell mem-
branes, prevented neuronal damage when given before and after
bacterial infection in animalmodels ofmeningitis. These products
might be used therapeutically for protection against neuronal cell
death by apoptosis if this mechanism was shown to be important
in humans (15–17). Accurate identification of proteins associated
with specific mechanisms of neuronal cell death in human CSF
could therefore provide evidence to support clinical trials of anti-
apoptotic drugs for improved patient outcome.
In our previous study,we found reduced complementC3 levels
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in patients who died of pneumococcal meningitis (5). C3 plays a
central role in the activation of the complement system. Process-
ing by C3 convertase is the central reaction in both classical and
alternative complement pathways. C3 aids innate immunity either
by the coating of pathogens with C3b and iC3b, which stimulates
phagocytosis, or by the release of proinflammatorymediators C3a
and C5a (18). Pathological sequelae are mediated in part by the
intrathecal activation of the complement cascade in response to a
bacterial challenge (19). The relationship between complement
C3 activity and pneumococcal meningitis is not fully understood.
Classical and lectin pathways are most commonly associated with
pneumococcal disease (20). Many pathogenic serotypes of pneu-
mococci are poor activators of the alternative complement path-
way (21) or degrade C3b into less opsonically active components
(22) and are therefore able to resist phagocytosis. The importance
of opsonization, however, is strongly supported by the finding
that the impairment of either the phagocytic system or opsonin
production predisposes the host to pneumococcal disease (23,
24).
This study tested three hypotheses: (i) candidate proteins pre-
viously identified by pilot proteomics can be confirmed in a larger
comparison of survivors and nonsurvivors, (ii) apoptotic proteins
in CSF are associated with death, and (iii) necrosis proteins found
in pneumococcal meningitis-affected CSF are associated with
death.
RESULTS
Clinical details of patients. CSF from 80 patients with microbio-
logically proven pneumococcal meningitis was analyzed byWest-
ern blotting. Forty of these CSF samples were from patients who
survivedwith noneurological impairment. The remaining 40 sub-
jects all died within 10 days. Clinical details of the patients are
provided in Table 1.
CSF total protein concentration. CSF from patients with
meningitis had a mean total protein concentration of 5.92 mg li-
ter1 compared to control (mean, 0.23 mg liter1; P  0.0001).
Nonsurvivors had a total protein concentration between 2.20 and
11.30 mg liter1 (mean, 6.38 mg liter1). Survivors had a total
protein concentration between 1.12 and 10.89 mg liter1 (mean,
5.46mg liter1). Themean total protein concentrationwas higher
in nonsurvivors than in survivors, but the two concentrations
were not significantly different (P  0.09; see Fig. S1 in the sup-
plemental material).
Expression of proteins of plasma origin in cerebrospinal
fluid. (i) Expression of transferrin in cerebrospinal fluid and
blood serum. Transferrin was measured in normal CSF (mean,
0.08 mg liter1), nonsurvivor CSF samples (mean, 1.25 mg li-
ter1), and survivor CSF samples (mean, 0.67mg liter1) (Fig. 1).
The mean concentration of transferrin in normal CSF was signif-
icantly lower than that in CSF from patients diagnosed with men-
ingitis (P  0.0001). The mean concentration of transferrin in
CSF from nonsurvivors was 2-fold higher than that in CSF from
survivors (P 0.0004).
Transferrin was measured in serum samples from nonsurvi-
vors (mean, 1.72mg liter1) and survivors (mean, 1.89mg liter1;
TABLE 1 Clinical details of survivors and deceased patientsa
Parameter
Subject group (n)
Normal (10) Nonsurvivors (40) Survivors (40)
Age, yr [mean (SD)] 27.8 (9.5) 30.1 (8.4) 33.3 (11.2)
Male sex, n 3 23 16
GCS [median (SD)] 9.0 (4.7) 8.0 (3.2) 11.0 (3.2)
Median time to presentation [h (range)] 60 (12–96) 72 (15–336) 48 (10–192)
Previous antimicrobials, no. 2 7 6
Steroid treatment [no. receiving (no. receiving placebo)] 17 (23) 21 (19)
HIV positive [no. (% of those tested)] 35 (100) 37 (100)
HIV status not known, no. 10 5 3
Survival at day 10, % 100 0 100
Hemoglobin [g/dl (range)] 10.82 (2.8–15) 11.01 (5.5–17.7)
CSF leukocytes [count/l (range)] 1,376.3 (20–9,980) 2,088.4 (15–10,500)
Neutrophils [count (% of those tested)] 92.17 (67–100) 91.97 (76–99)
a Clinical data collected from patients providing CSF samples that were used in this analysis. All meningitis subjects were diagnosed as having pneumococcal meningitis caused by
Streptococcus pneumoniae, all subjects were HIV positive, and all samples were collected before any treatment commenced. Normal CSF was obtained from patients who tested
negative for meningitis or any other pathogen. The HIV status of the normal patients was not known. Hemoglobin levels have been included as low hemoglobin levels are
associated with both advanced AIDS and poor outcome. GCS, Glasgow coma scale.
FIG 1 Transferrin levels in CSF. Transferrin was measured in normal CSF
(mean, 0.08 mg liter1). Transferrin was found in nonsurvivor CSF samples
(mean, 1.25 mg liter1) and survivor CSF samples (mean, 0.67 mg liter1).
There was a statistically significant difference between the mean level of trans-
ferrin in nonsurvivors and that in survivors (P  0.0004). The mean level of
transferrin in nonsurvivor CSF was 2-fold higher than that in survivor CSF.
There was a statistically significant difference between the mean level of trans-
ferrin in meningitis-affected CSF and that in normal CSF (P 0.0001).
Goonetilleke et al.
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P  0.183) (see Fig. S2 in the supplemental material). We tested
for correlation between the concentration of transferrin in serum
from patients and the corresponding CSF concentration in both
nonsurvivors and survivors and found none (see Fig. S3 and S4).
The mean concentration of transferrin in serum from nonsurvi-
vors was 1.5-fold higher than the corresponding level in CSF, but
the mean concentration of transferrin in survivors was 3-fold
higher in serum than in the corresponding CSF.
(ii) Expression of complement C3 in cerebrospinal fluid and
serum. Complement C3 was not found in normal CSF. C3 levels
in nonsurvivor CSF samples (mean, 0.04 mg liter1) were signif-
icantly lower than those in survivor CSF samples (mean,
0.21 mg liter1; P 0.0001) (Fig. 2).
There was no statistically significant difference between the
mean concentration of C3 in serum of nonsurvivors (mean,
1.47 mg liter1) and that in the serum of survivors (mean,
1.50 mg liter1; P 0.81) (see Fig. S5 in the supplemental mate-
rial). There was a statistically significant difference between the
mean concentrations of C3 in CSF and in the corresponding se-
rum samples (P 0.0001) see Fig. S6 and S7).
(iii) Expression of beta-2-glycoprotein in cerebrospinal
fluid. Beta-2-glycoprotein was measured in normal CSF (mean,
0.13 mg liter1), nonsurvivor CSF samples (mean, 0.83 mg li-
ter1), and survivor CSF samples (mean, 0.69 mg liter1). There
was a significant difference between themean beta-2-glycoprotein
levels in CSF from patients diagnosed with pneumococcal menin-
gitis and those in normal CSF (P 0.0001) but not between non-
survivors and survivors (P 0.10).
Cerebrospinal fluid levels of apoptosis proteins. Neither
caspase 3 nor apoptosis-inducing factor (AIF) was detected in the
80 meningitis-associated CSF samples (nonsurvivors or survi-
vors) or the 10 normal CSF samples (see Fig. S8 in the supplemen-
tal material). Western blotting for both caspase 3 and AIF was
repeated with two primary antibodies directed against different
regions of the respective protein structures with the same out-
come. The specificity of the antibodies was confirmed using an
antigenic blocking peptide. The blocking peptide binds to the ac-
tive site of the antibody, which inhibits the antibody activity, lead-
ing to quenching of protein expression. The sensitivity of detec-
tion was increased by the use of polyclonal antibodies directed
against caspase 3 and AIF at optimum levels of concentration and
exposure to the CSF proteins.
The limit of detection was determined by serial dilution of the
positive control. Both AIF and caspase 3 were detectable in the
positive cell lysate at protein concentrations as low as 100 ngl1.
The visualization of the proteins in CSF upon spiking normal CSF
with the control lysate would suggest that the proteins are not
being confounded by larger proteins in CSF (see Fig. S9 in the
supplemental material).
Cerebrospinal fluid levels of thenecrosis proteinCKBB.Cre-
atine kinase BB (CKBB) was not detected in normal CSF samples
but was present in over 40% of CSF samples from patients diag-
nosedwithmeningitis. Themean concentrations of CKBB in non-
survivors and survivors were 0.89 mg liter1 and 0.19 mg liter1,
respectively, but there was no statistically significant difference
between the two groups (P 0.16), owing to the small number of
samples with detectable CKBB as shown in Fig. 3.
Proteomic candidate cerebrospinal fluid markers of clinical
outcome. Retinoid X receptor (RXR) gamma was not found in
normal CSF but was found in 73% of nonsurvivor CSF samples
(mean, 0.50 mg liter1, inclusive of all samples) and 83% of sur-
vivor CSF samples (mean, 0.36mg liter1, inclusive of all samples;
P 0.48).
Zinc finger protein 179 was not found in normal CSF but was
found in 98%of nonsurvivor CSF samples (mean, 0.52mg liter1,
inclusive of all samples) and 70% of survivor CSF samples (mean,
0.41 mg liter1, inclusive of all samples; P 0.59).
Chitotriosidase was not found in normal CSF. Chitotriosidase
was found in 50% of nonsurvivor CSF samples (mean, 0.88 mg li-
FIG 2 Complement C3 levels in CSF. C3 was not found in normal CSF (n
10). C3was found in nonsurvivor CSF samples (n 40;mean, 0.04mg liter1)
and survivor CSF samples (n 40; mean, 0.21 mg liter1). There was a statis-
tically significant difference between themean concentration of C3 in nonsur-
vivors and that in survivors (P 0.0001). Themean level of C3 in nonsurvivor
CSF was 5-fold lower than that in survivor CSF.
FIG 3 Creatine kinase BB levels in CSF. CKBB was discovered in over 40% of
the CSF samples. CKBB levels were not significantly higher in nonsurvivors
(mean, 0.89 mg liter1, inclusive of all samples) than in survivors (mean,
0.19 mg liter1, inclusive of all samples) (P  0.16). CKBB was not found in
normal CSF.
Complement Depletion in Pneumococcal Meningitis
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ter1, inclusive of all samples) and 75% of survivor CSF samples
(mean, 0.47 mg liter1, inclusive of all samples; P 0.09).
DISCUSSION
In our previous pilot proteomic analysis of CSF in patients diag-
nosed with pneumococcal meningitis, we observed several pro-
teins having an associationwith survival (5). In this study, we have
shown that a subset of these proteins were detectable in a larger
sample size; however, only the proteins transferrin and comple-
ment C3 showed a significant association with survival.
Blood-brain barrier integrity and transferrin. The blood-
brain barrier is responsible for maintaining biochemical homeo-
stasis within the CNS (25). Penetration of the blood-brain barrier
by a bacterial pathogen reflects a complex interplay between the
host endothelium and microbial surface components (26).
Transferrin is responsible for the transport of iron from sites of
absorption and heme degradation to those of storage and utiliza-
tion (27, 28). The increased level of transferrin in nonsurvivors
was an indicator of blood-brain barrier damage, and this damage
may have been a contributing factor to death from pneumococcal
meningitis. The observation, however, that CSF levels did not cor-
relate with serum levels implies that, although transferrin levels in
CSF relate to blood-brain barrier integrity and simple diffusion,
there has not been a complete breakdown of the blood-brain bar-
rier regulation of proteins in most cases.
Another possible explanation for the lack of association be-
tween CSF and plasma transferrin levels may be the negative
acute-phase property of transferrin, i.e., transferrin has a tendency
to decrease during inflammation and CSF/serum time courses of
transferrin regulation are likely not synchronous (27).
This partial breakdown of the blood-brain barrier correlated
with the observation that the levels of the serum protein beta-2-
glycoprotein (important in processes such as coagulation and ath-
erosclerosis) did not vary between nonsurvivors and survivors,
indicating that the blood-brain barrier retains some ability to filter
serum (29).
Complement C3 depletion and outcome. Complement C3
was observed to be lower in nonsurvivors than in survivors. To
confirm that this change in C3 concentration was localized to the
CNS, analysis was carried out on corresponding blood samples.
The lack of any association between C3 in serum and that in CSF
indicated that changes in the level of C3 were localized to CSF.
The first evidence for a functional role of the complement sys-
tem in limiting pneumococcal outgrowth within the CNS was
described by Tuomanen et al. (23). In rabbits depleted of C3 by
cobra venom factor, intracisternal inoculation of S. pneumoniae
resulted in higher bacterial titers than those in complement-
sufficient control animals (30). Thus, lower levels of C3 in non-
survivors than in survivors may have resulted in higher bacterial
titers ormay have been due to greater consumption of C3 inmore
severe illness. A positive-feedback mechanism can be proposed
where nonsurvivors had very high numbers of bacterial CFU in
their CSF, which led to activation and breakdown of C3. Some
pneumococcal species can degradeC3 directly; for example, Angel
et al. demonstrated that type 3 pneumococci express C3-
degrading activity associated with the cell wall (22, 31). Few of the
infections in this study were due to type 3, however, as this type is
not common in Malawi (32).
Patients were recruited at the point of admission to the hospi-
tal. Clinical information indicative of AIDS preceding the acute
episode was sought in all patients. Twenty-four patients had evi-
dence of chronic illness or one or more HIV-associated infections
(11 had a history of tuberculosis [TB] treatment, 10 had shingles,
3 had pneumonia, and 3 hadmeningitis).We can only speculate as
to the nature of the effect of HIV and of encephalopathy caused by
HIV on the final results, as CNS HIV infection and immune acti-
vation have been demonstrated to also lead to brain injury (33).
Serum albumin levels are used to distinguish viral meningitis
frombacterialmeningitis inCSF (34).Unfortunately, the albumin
data frompatients were not available owing to the limited hospital
laboratory support available at the study site. These albumin data
could have been used to compare the blood plasma levels with the
final CSF levels. This would allow a measure of the compartmen-
talization of the CSF protein changes and also a measure of the
effect of viral infection prior to meningitis.
Cell death markers in cerebrospinal fluid. Despite animal
models indicating that caspase 3 and AIF would be detectable in
CSF during pneumococcal meningitis in humans (17, 35, 36),
there was no evidence observed of these classical apoptosis mark-
ers. The data obtained from the analysis of apoptosis proteins
indicate that since caspase 3 and AIF are not present, there was no
leakage of cell death material into CSF. This was surprising con-
sidering the level of data in animalmodelswhich suggest that these
proteins would be identified in CSF. It was possible, however, that
these were longer-term animal models where the levels of bacteria
and pneumolysin were lower than those in the nonsurvivor
groups analyzed in this study (35, 37).
It was also possible that small foci of apoptosis did not result in
a large increase of caspase 3 or AIF, and this could be confirmed
with suitable postmortem material. Alternatively, an increase in
metabolic proteins, previously identified in the pilot proteomics
analysis (5), may have led to an increase in proteosomal degrada-
tion of AIF and caspase 3. These degradation pathways may occur
via a ubiquitination process such as that mediated by X-linked
inhibitor of apoptosis (XIAP) utilizing E3 ubiquitin ligase activity.
This enables apoptosis inhibitors to catalyze ubiquitination of
themselves, caspase 3, caspase 7, and AIF (38).
Caspase inhibitors and citicolinemay have neuroprotective ef-
fects and may potentiate neurorecovery. This has led to the eval-
uation of caspase inhibitors and citicoline as potential treatment
for neuronal injury during meningitis. On the basis of our data,
however, there is no theoretical rationale for the use of caspase
inhibitors or citicoline in patients with pneumococcal meningitis.
Further exploration may require development of an in vitro
model of the CSF inflammatory process to determine if CSF from
nonsurvivors causes injury to neurons and endothelial cells more
than does that from survivors. The addition of caspase inhibitors
to this model can be used to see if a difference is observed. Anti-
apoptosis treatment could be used to determine if the lack of
caspase or AIF in CSF is related to tissue damage. This will allow
the opposite conclusion to be validated.
In rodentmodels, neuronal necrosis has been shown to involve
caspase 3 and AIF (39). Therefore, the absence of these proteins
provides evidence that necrosis also does not occur at significant
levels. To distinguish necrosis from apoptosis, we used creatine
kinase as a specific marker of neuronal necrosis. CKBB is the
brain-specific isotype of the protein (40). This protein is a cyto-
plasmic protein released during tissue necrosis. CKBB can leak out
of cells under ischemic episodes or injury to the brain (41). Our
Goonetilleke et al.
4 ® mbio.asm.org March/April 2012 Volume 3 Issue 2 e00272-11
 
m
bio.asm
.org
 o
n
 August 10, 2012 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
data suggest that CKBB is not a useful prognostic indicator in
pneumococcal meningitis.
Proteins of cerebrospinal fluid origin showed no association
with outcome. The proteins analyzed as indicators of proteins in
CSF included RXR gamma, zinc finger protein 179, and chitotrio-
sidase. RXR gamma receptors are involved in the expression of
anti-inflammatory activity by immune cells and mediate the cel-
lular effects of retinoid compounds (42). Zinc finger protein 179 is
predominantly expressed in the brain. The gene for this protein
encodes amember of the RING finger protein family of transcrip-
tion factors and is associated with neuronal differentiation. The
protein has been implicated in a variety of functions such as tran-
scriptional regulation, DNA repair, site-specific recombination,
and signal transduction (43). RXR gamma and zinc finger protein
179 are located primarily in the nucleus. Their low-level detection
may be due to an incomplete leakage of cell material into the CSF,
although the similar levels of these proteins suggest that their ex-
pression has no clear association with outcome (42, 43).
Chitotriosidase is an enzyme which degrades chitin and chito-
triose and may participate in the defense against nematodes and
other pathogens (44). Chitotriosidase can be considered an in-
flammatory protein since it is secreted only by activated macro-
phages and may be used as an important predictor of neuronal
disease severity (45). It was expected that chitotriosidase would
have greater expression in CSF associated with clinically proven
pneumococcal meningitis, but the expression was very low or ab-
sent.
Conclusions. This study has shown that blood-brain barrier
damage appears to alter the level of protein in CSF and acts as a
confounding factor in protein analysis of the CNS during menin-
gitis. The increased level of transferrin in nonsurvivors suggested
blood-brain barrier damage but did not provide a direct marker
for the degree of damage.
In addition, this study has shown that CSF levels of comple-
ment C3 are associated with outcome in pneumococcal meningi-
tis. The data suggest that complement C3 plays an important role
in the pathogenesis of bacterial meningitis and may serve as a
prognostic marker.
The absence of standard apoptosis markers in CSF suggested
that treatment involving citicoline and caspase inhibitors is un-
likely to provide benefit to patients with pneumococcal meningi-
tis. The presence of CKBB indicated that cortical necrosis occurs
to a significant degree in many patients with pneumococcal men-
ingitis, but this was not clearly associated with outcome.
MATERIALS AND METHODS
Patient information. (i) Patients and sample collection. Patients were
recruited to a double-blind, randomized, placebo-controlled trial of dexa-
methasone adjuvant therapy. CSF and blood serum samples collected
from patients as part of clinical diagnosis were saved for later study. The
study was conducted in adults with bacterial meningitis presenting at the
Queen Elizabeth Central Hospital in Blantyre,Malawi, betweenMay 2002
and January 2005 (46). The study was approved by the research ethics
committees of the University of Malawi College of Medicine and the Liv-
erpool School of Tropical Medicine. Patients provided written informed
consent, or if they were unable to read or write, they provided indepen-
dently witnessed verbal consent before recruitment. Patients were treated
in the hospital for a minimum of 10 days and were evaluated at 40 days
and at 6 months. Clinically evident adverse events were recorded system-
atically throughout the trial period. At follow-up, patients had a standard-
ized neurologic examination and a hearing assessment. Patients who did
not return for follow-up appointments were visited at home. No other
underlying diseases were specifically sought other than HIV and malaria
(46).
(ii) Patient categories. Clinical data allowed the patients in the men-
ingitis trial to be classified into 3 clear phenotypes: survival to 40 days with
no neurological impairment or recorded disability (n 103), deafness or
disability at 40 days (n  113), and death within 40 days (n  157). We
chose to study only patients who had confirmed pneumococcal meningi-
tis (Gram-positive diplococci seen in CSF or pneumococci cultured from
either CSF or blood) and to compare those who survived free of neuro-
logical deficit with those who died, as we anticipated that these pheno-
types would show the clearest differences. Control CSF was obtained with
consent from patients who presented to the hospital with a headache but
subsequently tested negative for meningitis or any other pathogen. CSF
samples were stored at20°C within an hour of sampling and at80°C
from 24 h until analysis.
Protein target selection. (i) Proteomically derived targets. Proteins
were previously identified as having different levels of expression between
nonsurvivors and survivors in a pilot proteomic comparison of CSF (5).
These proteins were formally identified after manual excision from
stained two-dimensional (2D) gels. The proteins were subject to in-gel
tryptic digestion and sequenced by matrix-assisted laser desorption ion-
ization–time of flight (MALDI-TOF) mass spectrometry (MS) or liquid
chromatography (LC)-MS. Peptide data were analyzed with Mascot soft-
ware (Matrix Science, London, United Kingdom). In this comparison of
CSF from patients who survived with CSF from those who died, we chose
to compare specific proteins that showed important differences (3-fold
expression) in exploratory 2D gel analysis. The targets selected from these
proteins for further analysis included three proteins of plasma origin and
three proteins of CSF origin. The three plasma proteins analyzed were (i)
transferrin, (ii) complement C3, and (iii) beta-2-glycoprotein. The three
proteins of cerebrospinal fluid origin analyzed were (i) retinoic acid X
receptor gamma, (ii) zinc finger protein 179, and (iii) chitotriosidase.
(ii) Cell death pathway targets. Proteins associated with apoptosis
and necrosis were analyzed in CSF. We analyzed CSF for the apoptosis-
associated proteins apoptosis-inducing factor (AIF) and caspase 3 (35).
We analyzedCSF for the protein creatine kinase BB (CKBB) as evidence of
neuronal necrosis (45).
Western blotting of cerebrospinal fluid.Archived CSFwas thawed at
4°C. The concentration of protein in each CSF sample was determined
using the Bradford assay. SDS-PAGE gels of whole CSF protein were sep-
arated using optimized gel concentrations for each Western blot. The
transfer membranes used in all the experiments of this analysis were ni-
trocellulose paper (NCP; GE Life Sciences, Piscataway, NJ). AIF and
caspase 3 protein blots were retested using polyvinylidene difluoride
(PVDF) membranes (GE Life Sciences).
(i) Antibodies. Primary antibodies used in this analysis were directed
against caspase 3 (9665 and sc-22140) and apoptosis-inducing factor
(AIF; 4642 and sc-9416) and came fromCell Signaling (Danvers,MA) and
Santa Cruz Biotechnology (Santa Cruz, CA). Creatine kinase BB (CKBB;
ab38212), zinc finger protein 179 (ab42499), retinoic acid X receptor
gamma (ab15518), chitotriosidase (CHIT1; ab72574), and transferrin
(ab1223) antibodies came from Abcam (Cambridge, United Kingdom).
Beta-2-glycoprotein (MCA2114; AbD Serotec, Oxford, United Kingdom)
and complement C3 (C7761-1VL; Sigma-Aldrich, Poole, United King-
dom) antibodies were also used. Secondary antibodies were purchased
fromDako (Cambridge,UnitedKingdom) andNordic Immunology (Til-
burg, Netherlands).
(ii) Positive-control protein markers. The positive-control lysate
used for caspase 3 was Jurkat apoptosis cells treated with etoposide (9663;
Cell Signaling). ForAIF, CKBB, andRXRgamma, the positive-control cell
lysate was HeLa whole-cell lysate (sc-2200; Santa Cruz Biotechnology).
For zinc finger protein 179, the positive-control lysate used was HepG2
cell lysate (sc-2227; Santa Cruz Biotechnology). For chitotriosidase, a re-
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combinant chitotriosidase protein was used (3559-GH; R&D Systems,
Minneapolis, MN).
Blood plasma (obtained from a healthy volunteer) was used as a con-
trol for complement C3, transferrin, and beta-2-glycoprotein. For trans-
ferrin, a recombinant transferrin protein was used as an additional posi-
tive control (Sigma-Aldrich; 90190).
Quantitative measure of protein expression in cerebrospinal fluid.
The blot images were captured using a gel documentation camera (Syn-
gene, Cambridge, United Kingdom) and analyzed using the open source
software ImageJ (v.1.43; NIH, Bethesda, MD; free download available at
http://rsb.info.nih.gov/ij/) (47). In these Western blots, the reference
band used was the positive control for the protein under analysis. The
expression value obtained for CSF was converted to an approximate
quantity using a calibration curve generated from the positive control
(http://lukemiller.org/journal/2007/08/quantifying-western-blots
-without.html). This value was then converted to a native concentration
in CSF by correction of the dilution of CSF used in theWestern blot assay.
The quantity of protein measured was estimated for each CSF sample as a
relative intensity. Data regarding expression are given in Table S1 in the
supplemental material.
Quantitative analysis of transferrin and complement C3 in blood
serum. Analysis was performed on corresponding serum samples col-
lected as part of routine diagnosis. Analysis was performed using an im-
munoturbidimetric assay. Measurements were collected using a Cobas
c501 modular analyzer (Roche, West Sussex, United Kingdom). Preci-
norm protein kits (Roche) were used for both complement C3 and trans-
ferrin analysis. Themeasurement range for C3was 0.9 to 1.8 g liter1, and
that for transferrin was 2.0 to 3.6 g liter1.
Statistical analysis. Pairwise comparisons were performed using an
unpaired t test with Welch’s correction. This was calculated using Prism
software (v.5.0; GraphPad, La Jolla, CA).
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